Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 20/20 | 1.00 |
| ▸ | RARG | P13631 | 19/20 | 1.00 |
| ▸ | RARA | P10276 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100837 | 1.00 | RARB (1.00) | RARBRARGRARA | |
| SCHEMBL7642585 | 0.91 | RARB (0.84) | RARBRARGRARA | |
| SCHEMBL6234641 | 0.91 | RARB (1.00) | RARBRARGRARA | |
| SCHEMBL6232868 | 0.91 | RARB (1.00) | RARBRARGRARA | |
| SCHEMBL6210444 | 0.91 | RARA (1.00) | RARBRARGRARA | |
| SCHEMBL6233323 | 0.90 | RARB (1.00) | RARBRARGRARA | |
| SCHEMBL8472049 | 0.90 | RARB (1.00) | RARBRARGRARA | |
| SCHEMBL31725103 | 0.89 | RARB (0.80) | RARBRARGRARA | |
| SCHEMBL6237239 | 0.88 | RARB (1.00) | RARBRARGRARA | |
| SCHEMBL6236971 | 0.88 | RARB (1.00) | RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034081-A1 | COMPOSITIONS AND METHODS RELATED TO INHIBITION OF ADENOMAS AND ADENOCARCINOMAS | UNIV COLUMBIA (US) | 2026-02-05 | — | — | US | claimed |
| EP-4569090-A2 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-119654404-A | Methods and compositions for producing oligodendrocyte progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-03-18 | — | — | CN | claimed |
| CN-117126801-B | Preparation method, product and application of high-regeneration subcultured fibrochondrocytes | 呈诺再生医学科技(北京)有限公司 | 2025-01-21 | — | — | CN | claimed |
| US-12115140-B2 | Method of treating adenoid cystic carcinoma | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-10-15 | — | — | US | claimed |
| WO-2024211636-A1 | COMPOSITIONS AND METHODS RELATED TO INHIBITION OF ADENOMAS AND ADENOCARCINOMA | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2024063818-A9 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-117887658-A | Method for differentiating human pluripotent stem cells into natural killer cells and application thereof | 浙江霍德生物工程有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-20100144683-A1 | METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT | ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) | 2010-06-10 | — | — | US | claimed |
| US-20090118264-A1 | Medicament having neovascularization promoting action | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-05-07 | — | — | US | claimed |
| EP-2046309-A2 | USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES | Association pour la recherche à l'IGBMC (ARI) (FR) | 2009-04-15 | — | — | EP | claimed |
| EP-1891944-A1 | Use of Vitamin D3 agonist in a mammalian model for atopic diseases and of Vitamin D3 antagonists for the treatment of atopic diseases | Association pour la recherche à l'IGBMC (ARI) (FR) | 2008-02-27 | — | — | EP | claimed |
| WO-2008012645-A2 | USE OF VITAMIN D3 AGONIST IN A MAMMALIAN MODEL FOR ATOPIC DISEASES AND OF VITAMIN D3 ANTAGONISTS FOR THE TREATMENT OF ATOPIC DISEASES | ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI) (FR) | 2008-01-31 | — | — | WO | claimed |
| EP-0874626-B1 | USE OF INHIBITORS OF RETINOIC ACID ACTIVITY FOR WOUND HEALING | CT INTERNAT DERECH S DERMATOLO (FR) | 2004-12-29 | — | — | EP | claimed |
| WO-2004045595-A1 | USE OF AN RAR RECEPTOR ANTAGONIST FOR POTENTIATING THE ACTION OF TGFβ | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-03 | — | — | WO | claimed |
| EP-0892633-B1 | USE OF INHIBITORS OF THE ACTIVITY OF RETINOIC ACID FOR TREATING SENSITIVE SKIN AND/OR ACUTE DAMAGE INDUCED BY UV RADIATION | GALDERMA RECH DERMATOLOGIQUE (FR) | 2003-03-05 | — | — | EP | claimed |
| US-6248749-B1 | TOPICALLY APPLYING RETINOID ANTAGONIST TO SENSITIVE SKIN TO TREAT ALLERGIES/SUNBURN | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 2001-06-19 | — | — | US | claimed |
| US-5973007-A | SURGERY, TRAUMA WOUNDS | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1999-10-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034081-A1 | COMPOSITIONS AND METHODS RELATED TO INHIBITION OF ADENOMAS AND ADENOCARCINOMAS | RARB, RARA, ADGRF1 | RARB 1/4885RARG 4/4885RARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.